|
We are working on a redesign process for our website and daily newsletter. The result will be new features and greater access to more timely content. We apologize in advance for any temporary interruptions that may occur during this process.
|
|
By David Fried, editor The Buyback Letter
The decidedly negative and skeptical view the mainstream financial press takes when virtually any financial news is released may be hurting, not helping us invest more wisely.
There is good news in the financial markets, but often it is either not highlighted, or obscured by a myopic focus on a single week’s figures taken out of context.
|
|
Read more...
|
|
By Bryan Perry, editor The Cash Machine
I'm adding the BlackRock Global Opportunities Equity Trust (NYSE: BOE) to our Aggressive High-Yield Portfolio.
This closed-end fund has all the right stuff against the current investing landscape -- exposure to the U.S. and other faster-growing global economies, broad diversification, a healthy dividend yield of 11.38% derived from a time-tested covered call strategy and top flight management.
|
|
Read more...
|
|
By Kelley Wright, editor Investment Quality Trends
Our primary purpose is to assist subscribers in growing their capital and income base from which to derive cash for their current and future needs.
To that end we believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation.
|
|
Read more...
|
|
By Louis Basense, contributing editor The Oxford Club
It's not secret that small caps perform best coming out of recessions. Further, if we want to ride the small-cap rally for maximum gains, we should similarly rotate into small-cap value stocks.
Thankfully, it’s an easy transition to make. I say that because the most attractive small-cap value investment is sitting right under our noses. No one on Earth is better at discovering small-cap value investments than David Dreman.
|
|
Read more...
|
|
By Jim Oberweis, Jr., editor The Oberweis Report
We expect that 2010 will be better for technology stocks. Even after a strong year in 2009, they still have a long way to go to compensate for the carnage of 2008.
In particular, bet on companies building the latest generation semiconductors or facilitating greater network bandwidth. In particular, we like new pick Cirrus Logic (NASDAQ: CRUS).
|
|
Read more...
|
|
By Carl Delfeld, editor Chartwell ETF Advisors
It is a little like catching a falling knife in the wake of the sharp pull back in emerging markets, but you might want to take a small position in Brazil Small Cap (NYSE: BRF).
Brazil’s currency, the Real, remains one of the most attractive in the world up 27% in the past year and foreign exchange reserves are at $240 billion.
|
|
Read more...
|
|
By Geoff Seiler, BullMarket.com
Microsoft (NASDAQ: MSFT), already a holding in our model portfolio, recently reported a big jump in profitability for the final three months of 2009.
Investor reaction was muted, however, as there was a wide divergence in spending for the company's software products by enterprise and consumer clients.
|
|
Read more...
|
|
By Curtis Hesler, editor The Professional Timing Service
Where should you invest in 2010? Preferably, you should stick to the heart of the matter and focus on crude oil and gold.
Invest in assets that promise to increase in price as the dollar falls; this will insulate your portfolio from the damage that the ongoing deleveraging process will bring to the stock market and to other paper assets.
|
|
Read more...
|
|
By Roger Conrad, editor The Canadian Edge
Since I started Canadian Edge, my general view on the plethora of closed-end funds holding trusts and high-yielding corporations has been dismal. Too often, investors get the bad and ugly as well as the good.
Many have historically relied too much on leverage and capital gains to maintain payouts; many also takeas much as 2% to 3% of assets off the top in fees each year, one exception is my latest High Yield of the Month -- Blue Ribbon Income Fund (TSX: RBN-U, OTC: BLUBF).
|
|
Read more...
|
|
|